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In this issue of Chemistry & Biology, Alexander and
Cravatt [1] propose a model for the binding of carba-
mate inhibitors to fatty acid amide hydrolase (FAAH),
the enzyme that breaks down signaling lipids. Using
competitive activity-based protein profiling and click
chemistry, they designed potent and selective FAAH
inhibitors and characterized their off-target reactions.
Marijuana, Cannabinoid Receptors, Anandamide, and
FAAH. Marijuana has been used for thousands of years
for the physiological effects that occur when its active
component THC [2] overwhelms the brain’s cannabinoid
receptors [3–5] that normally are occupied by endoge-
nous ligands including anandamide [6]. Fatty acid amide
hydrolase (FAAH) is the key integral membrane enzyme
involved in the hydrolysis of anandamide [7] and other
fatty acid amides [8] including oleamide, a sleep factor,
and palitoylethanolamide, an anti-inflammatory sub-
stance [9].
The field made a quantum jump in 1996 when the Cra-
vatt laboratory cloned FAAH. They did it the old-fash-
ioned way—by purifying it first [10]. Three independent
laboratories found the catalytic amino acids in FAAH
to be unique in that, unlike most serine hydrolases, there
were two serines instead of the typical serine-histidine-
aspartic acid catalytic triad. The whole story was even-
tually elucidated by Cravatt laboratory, using mutagen-
esis, kinetics, and labeling experiments through which
they described a unique catalytic mechanism involving
a serine-serine-lysine triad. Serine 241 is the nucleophile
binding to anandamide and inhibitors.
Later work showed that FAAH knockout mice had el-
evated levels of anandamide and other fatty acid etha-
nolamides in the central and peripheral nervous system
[11]. From these and other transgenic experiments, it
was concluded that in FAAH2/2mice there was a canna-
binoid receptor-dependent reduction in pain sensation
caused by higher anandamide levels and reduced in-
flammation, which, in part, may be mediated by other
fatty acid amides normally metabolized by FAAH [12].
In 2002, the crystal structure of FAAH bound to an inhib-
itor revealed a dimeric protein with a hydrophobic cap
that constitutes a membrane binding region, presum-
ably reinforcing the binding of the N-terminal transmem-
brance binding domain (deleted for practical purposes
during crystallization). Most interestingly, the crystal
structure revealed an acyl chain binding (ACB) channel
for entry of hydrophobic substrates from the membrane
and a cytoplasmic access (CA) channel for both en-
trance of water for the hydrolysis of substrate and exit
of the hydrophilic breakdown products. For example,
anandamide would enter via the membrane through
the ACB to the active site where it would be hydrolyzed,
and the liberated hydrophobic fatty acid would exit
through the ACB to the membrane while hydrophilicethanolamide would exit to the cytoplasm by the CA
channel (see McKinney and Cravatt [9] for a comprehen-
sive review of this work).
First Generation FAAH Inhibitors Were Potent but
Nonselective. Enzymes are important targets for many
drugs such as cyclooxygenase (COX) inhibitors, angio-
tension-converting enzyme (ACE) inhibitors, and HIV
protease inhibitors. Starting with the serendipitous dis-
covery that phenylmethylsulfonylfluoride (PMSF) [7, 13]
is a FAAH inhibitor, hundreds of compounds have been
synthesized targeting FAAH. Already in 1994, based
upon studies with trifluormethylketones, a-keto esters,
and a-keto amides, it was predicted that FAAH inhibitors
would have significant therapeutic value in the areas of
analgesia, mood, nausea, memory, appetite, sedation,
locomotion, glaucoma, and immune function [14], and
some of this has already been borne out with a variety of
compounds in animal studies [15]. However, many of
thesecompounds,althoughpotent, could not bechecked
for specificity against the large number of other enzymes
that they may also inhibit. Interestingly it was discovered
that NSAIDs are weak FAAH inhibitors [16, 17].
Cravatt’s group pioneered new methods to measure
the potency and specificity of FAAH inhibitors against
the proteome (proteins expressed in different tissues)
[18]. Termed competitive activity-based protein profiling
(ABPP), the technique employs a fluorescent-labeled
fluorophosphonate that reacts with the broad family of
serine hydrolases including FAAH in tissue homoge-
nates. When putative FAAH inhibitors are incubated with
the probe, the off-target interactions (e.g., in the brain,
liver, and kidney) become evident as well as the strength
of the inhibitor for FAAH. Competitive ABPP has been
used successfully to show that many of the inhibitors de-
scribed above had off-target reactions [19]. In addition,
in collaboration with the Boger group at Scripps, many
new potent and selective inhibitors have been described,
such a OLE135, that have potent analgesic effects [20].
Putting It All Together. However, ABPP cannot be ap-
plied to live animals or cells in culture because the probe
with the fluorescent tag is too bulky. Click chemistry (CC)
provided the solution to this problem through a FAAH in-
hibitor bearing a stable small reactive group (e.g., an al-
kene). The molecule gets into cells and hits its target(s).
The tissue is then isolated and reacted with an azide-
tagged fluorescent group, and FAAH and other reactive
proteins are separated and identified (Figure 1). The pa-
per by Alexander and Cravatt [1] brings it all together.
They now describe a new series of selective and potent
FAAH inhibitors whose structures are based upon carba-
mates such as URB597, recently described to modulate
anxiety in an animal model [21–23]. It was proposed that
URB-related compounds carbonylate Ser241 and that
the compound resides in the enzymatic pocket of the
protein such that the aliphatic part of the molecule faces
the cytoplamic channel [21, 22]. However, Alexander and
Cravatt found that the URB inhibitors are, in fact, ori-
ented in the opposite direction. That is, the biaryl part
of URB597 is in the cytoplasmic channel, and the ali-
phatic part of the molecule is in the hydrophobic acyl
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Mice were administered an alkyne-modified variant of the inhibitor at increasing doses. After a period of time, the animals were sacrificed, the
tissue was isolated and homogenized and then reacted under CC conditions with an azide-modified reporter tag. Labeled proteins were sepa-
rated by SDS-PAGE and visualized by in-gel fluorescence scanning. Off-target reactivities were identified by trypsinolysis followed by LC-MS.
The figure was kindly provided by Jessica Alexander.chain binding channel. This model for URB597 binding
and orientation was consistent with the carbamylation
of Ser 241, observed by MALDI-TOF mass spectromeric
mapping of a tryptic peptide. To further confirm their
model, they synthesized other carbamates with longer
aliphatic side chains (similar to those found on known
FAAH inhibitors) that were more potent than URB597.
Using one of these FAAH inhibitors (JP104), they
showed, in an in vitro ABPP assay, that it was specific
for brain FAAH. Experiments using FAAH knockout mice
then showed that even at high concentration of JP104
there were no other targets in the brain, but that there
were heretofore unknown targets in other organs such
as liver and kidney. The authors isolated and identified
some of these off-target reactants including carboxyles-
terase 6 and esterase 31; neither of which share any se-
quence homology with FAAH. Using JP104 as a click
chemistry probe in mice, they found a window where
its concentration could be adjusted to bind brain FAAH
selectively (1 mg/kg) while the reactions in liver and kid-
ney with proteins other than FAAH could be minimized.
Using JP104, for example, it will now be possible to
search for other, even more specific FAAH inhibitors that
have even fewer side reactions in peripheral tissues.
These authors are ‘‘on-target’’ with their speculation that
covalent enzyme inhibitors will be useful as in vivo func-
tional probes, paving the way for the design of therapeu-
tic agents in other areas such as cancer invasiveness [24].
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